Myriad to Appeal District Court's Decision in Anti-Gene Patenting Lawsuit
June 23, 2010
Myriad to Appeal District Court's Decision in Anti-Gene Patenting Lawsuit
Myriad Genetics has made good on its promise to appeal a federal district court's recent determination that seven of its BRCA1/2 gene patents are invalid.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- USPTO Hearing on Confirmatory Gene Testing Raises Calls for Reform Outside Patent System
February 22, 2012 / Pharmacogenomics Reporter - Narrow Ruling in Bilski Is a Win for Dx Developers, Despite Ambiguity on Gene-Patent Questions
June 30, 2010 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - GenomeWeb Feature: Regardless of Gene Patent Challenges, Myriad Faces Shifting Competitive Landscape
April 17, 2013 / Pharmacogenomics Reporter - Hearing on Second-Opinion Genetic Testing Highlights Risks of Athena's Exclusive Licensing Practices
January 16, 2013 / Pharmacogenomics Reporter